Bio-Rad Laboratories Future Growth
Future criteria checks 3/6
Bio-Rad Laboratories is forecast to grow earnings and revenue by 32.8% and 3.8% per annum respectively. EPS is expected to grow by 32.6% per annum. Return on equity is forecast to be 3.3% in 3 years.
Key information
32.8%
Earnings growth rate
32.6%
EPS growth rate
Life Sciences earnings growth | 21.9% |
Revenue growth rate | 3.8% |
Future return on equity | 3.3% |
Analyst coverage | Low |
Last updated | 22 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,893 | 326 | N/A | N/A | 4 |
12/31/2025 | 2,796 | 285 | N/A | N/A | 5 |
12/31/2024 | 2,663 | 294 | N/A | N/A | 5 |
3/31/2024 | 2,605 | -322 | 185 | 347 | N/A |
12/31/2023 | 2,671 | -637 | 218 | 375 | N/A |
9/30/2023 | 2,720 | -159 | 223 | 374 | N/A |
6/30/2023 | 2,769 | -428 | 153 | 287 | N/A |
3/31/2023 | 2,779 | -191 | 125 | 242 | N/A |
12/31/2022 | 2,802 | -3,628 | 80 | 194 | N/A |
9/30/2022 | 2,805 | -6,021 | 152 | 286 | N/A |
6/30/2022 | 2,871 | -1,930 | 364 | 505 | N/A |
3/31/2022 | 2,896 | -91 | 459 | 606 | N/A |
12/31/2021 | 2,923 | 4,254 | 536 | 670 | N/A |
9/30/2021 | 2,980 | 6,659 | 670 | 783 | N/A |
6/30/2021 | 2,880 | 4,045 | 590 | 689 | N/A |
3/31/2021 | 2,701 | 4,098 | 533 | 626 | N/A |
12/31/2020 | 2,546 | 3,814 | 480 | 585 | N/A |
9/30/2020 | 2,380 | 3,521 | 378 | 450 | N/A |
6/30/2020 | 2,294 | 1,947 | 323 | 414 | N/A |
3/31/2020 | 2,329 | 1,579 | 383 | 478 | N/A |
12/31/2019 | 2,312 | 1,759 | 368 | 458 | N/A |
9/30/2019 | 2,304 | 377 | 272 | 403 | N/A |
6/30/2019 | 2,289 | 905 | 251 | 366 | N/A |
3/31/2019 | 2,292 | 574 | 169 | 288 | N/A |
12/31/2018 | 2,289 | 366 | 156 | 285 | N/A |
9/30/2018 | 2,294 | 1,277 | 148 | 250 | N/A |
6/30/2018 | 2,283 | 1,030 | 116 | 216 | N/A |
3/31/2018 | 2,212 | 767 | 98 | 201 | N/A |
12/31/2017 | 2,160 | 122 | N/A | 104 | N/A |
9/30/2017 | 2,110 | 17 | N/A | 130 | N/A |
6/30/2017 | 2,085 | 13 | N/A | 153 | N/A |
3/31/2017 | 2,097 | 26 | N/A | 168 | N/A |
12/31/2016 | 2,068 | 26 | N/A | 216 | N/A |
9/30/2016 | 2,067 | 98 | N/A | 157 | N/A |
6/30/2016 | 2,028 | 97 | N/A | 188 | N/A |
3/31/2016 | 2,018 | 108 | N/A | 149 | N/A |
12/31/2015 | 2,019 | 109 | N/A | 186 | N/A |
9/30/2015 | 2,047 | 103 | N/A | 190 | N/A |
6/30/2015 | 2,108 | 97 | N/A | 199 | N/A |
3/31/2015 | 2,139 | 100 | N/A | 237 | N/A |
12/31/2014 | 2,175 | 89 | N/A | 273 | N/A |
9/30/2014 | 2,179 | 80 | N/A | 304 | N/A |
6/30/2014 | 2,154 | 61 | N/A | 268 | N/A |
3/31/2014 | 2,142 | 64 | N/A | 211 | N/A |
12/31/2013 | 2,133 | 78 | N/A | 169 | N/A |
9/30/2013 | 2,104 | 91 | N/A | 194 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BUW is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: BUW is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BUW is expected to become profitable in the next 3 years.
Revenue vs Market: BUW's revenue (3.8% per year) is forecast to grow slower than the German market (5.2% per year).
High Growth Revenue: BUW's revenue (3.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BUW's Return on Equity is forecast to be low in 3 years time (3.3%).